GSK sells off US rights to migraine drug
This article was originally published in Scrip
GlaxoSmithKline has sold its US rights to migraine drug Treximet (sumatriptan/naproxen) to Pernix Therapeutics for $250m. GSK licensed the rights from Pozen under a collaboration that began in 2003. US sales in 2013 were $79m, so the deal almost doubles Pernix's revenues.